NCT03781947View on ClinicalTrials.gov

A Study of Parenterally-administered Teverelix TFA in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 19, 2018

Primary Completion Date

March 16, 2020

Study Completion Date

March 16, 2020

Conditions
Healthy
Interventions
DRUG

teverelix TFA

A single s.c. or i.m. injection of teverelix TFA administered on Day 1

Trial Locations (1)

HA1 3UJ

PAREXEL International Early Phase Clinical Unit (EPCU), London

All Listed Sponsors
lead

Antev Ltd.

INDUSTRY

NCT03781947 - A Study of Parenterally-administered Teverelix TFA in Healthy Male Volunteers | Biotech Hunter | Biotech Hunter